KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Inventory (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Inventory data on record, last reported at $606.3 million in Q4 2025.

  • For Q4 2025, Inventory fell 1.0% year-over-year to $606.3 million; the TTM value through Dec 2025 reached $606.3 million, down 1.0%, while the annual FY2025 figure was $606.3 million, 1.0% down from the prior year.
  • Inventory reached $606.3 million in Q4 2025 per AMRX's latest filing, down from $614.5 million in the prior quarter.
  • Across five years, Inventory topped out at $614.5 million in Q3 2025 and bottomed at $489.4 million in Q4 2021.
  • Average Inventory over 5 years is $558.7 million, with a median of $560.6 million recorded in 2023.
  • Peak YoY movement for Inventory: grew 17.89% in 2021, then decreased 1.0% in 2025.
  • A 5-year view of Inventory shows it stood at $489.4 million in 2021, then rose by 8.45% to $530.7 million in 2022, then grew by 9.54% to $581.4 million in 2023, then rose by 5.34% to $612.5 million in 2024, then dropped by 1.0% to $606.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $606.3 million in Q4 2025, $614.5 million in Q3 2025, and $609.0 million in Q2 2025.